Amneal's Generic Tiopronin Receives Approval in US
FDA Confirms Paragraph IV Patent Litigation for Tiopronin Tablets
Par Pharmaceutical`s Generic Adapalene|Benzoyl Peroxide Receives Approval in the U.S.
SAN ANTONIO (September 22, 2016) – As students across the United States revel in the excitement of the “back-to-school” season, anxious parents and school nurses are faced with the annual spike in cases of head lice that coincide with the return to class. Head lice are tiny, wingless insects that live on the human scalp and spread between people by head-to-head contact or the sharing of hats, combs, brushes, or towels. August and September are traditionally months with the highest lice infestation rates. According to HeadLice.org, September is now “Head Lice Prevention Month.”
Retrophin, based in San Diego, announced that the U.S. Food and Drug Administration (FDA) had given its 100 mg and 300 mg tablets of Thiola EC (tiopronin) the thumbs-up to treat cystinuria. Cystinuria is a rare inherited disease that results in a buildup of cystine levels in the urine, causing the development of recurring cystine kidney stones.
Mission Pharmacal `s generic Tiopronin Receives Approval in US
Compounding pharmacy Imprimis Pharmaceuticals Inc said on Wednesday it plans to make a cheaper alternative to Retrophin Inc's kidney stone drug, Thiola.nnRetrophin, under former Chief Executive Martin Shkreli, raised the price of the drug from $1.50 to $30 per tablet after buying the rights from Mission Pharmacal Co in 2014, Imprimis said.
Retrophin Inc (NASDAQ:RTRX) was downgraded by research analysts at Vetr from a “strong-buy” rating to a “buy” rating in a report released on Monday, MarketBeat.Com reports. They presently have a $25.00 target price on the biopharmaceutical company’s stock. Vetr‘s price target indicates a potential upside of 11.86% from the company’s current price.
Back when Martin Shkreli was CEO of Retrophin, he managed to grab a few headlines by buying an old rare-disease drug, Thiola, and raising the price 2000%. Now that he's on to his next company, Turing Pharmaceuticals, he's done himself one better, by buying another old drug and boosting the price 5000%.